News

Patient Death Prompts Hold on Arcellx’s CART-ddBCMA for R/R Multiple Myeloma

Patient Death Prompts Hold on Arcellx’s CART-ddBCMA for R/R Multiple Myeloma

Victoria Johnson
June 20th 2023

The company believes that limitations on bridging therapies were a contributing factor to the death.

Jason Westin, MD, FASCP, on Axi-cel's Place in the Evolving Landscape of Care for Large B-cell Lymphoma

Jason Westin, MD, FASCP, on Axi-cel's Place in the Evolving Landscape of Care for Large B-cell Lymphoma

Jason Westin, MD, MS, FACP
June 20th 2023

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed recent and ongoing studies that are upending the paradigm in LBCL care.

2023 World Sickle Cell Day: The Home Stretch for Gene Therapy in SCD?

2023 World Sickle Cell Day: The Home Stretch for Gene Therapy in SCD?

Victoria Johnson
June 19th 2023

More work remains to be done to improve accessibility to populations and countries that have the highest unmet need with SCD treatment.

BioSenic Puts Trial for MSC-Derived Therapy ALLOB on Hold Following Disappointing Efficacy Results

BioSenic Puts Trial for MSC-Derived Therapy ALLOB on Hold Following Disappointing Efficacy Results

Noah Stansfield
June 19th 2023

The company will instead prioritize further development of its oral arsenic trioxide platform for cGvHD.

Susan Bal, MD, on Promising Efficacy With GPRC5D-CAR Therapy in R/R Multiple Myeloma

Susan Bal, MD, on Promising Efficacy With GPRC5D-CAR Therapy in R/R Multiple Myeloma

Susan Bal, MD
June 19th 2023

The assistant professor of medicine at University of Alabama – Birmingham discussed efficacy findings on BMS-986983 and more research to be done.

MDA, CureDuchenne, PPMD Collaborate to Reduce AAV Antibodies to Enable Gene Therapy

MDA, CureDuchenne, PPMD Collaborate to Reduce AAV Antibodies to Enable Gene Therapy

Victoria Johnson
June 18th 2023

The advocacy groups are funding a 1-year study to be led by Barry Byrne, MD, PhD, at University of Florida.

Mary “Nora” Disis, MD, on Reevaluating the Potential of CAR-T Approaches in Ovarian Cancer

Mary “Nora” Disis, MD, on Reevaluating the Potential of CAR-T Approaches in Ovarian Cancer

Mary “Nora” Disis, MD
June 18th 2023

The director of University of Washington Medicine’s Cancer Vaccine institute discussed the importance of continuing to develop new CAR-T approaches in the ovarian cancer field despite initial setbacks.

Harnessing a Unique Approach With A2B530 to Bring CAR T Treatment to Solid Tumors

Harnessing a Unique Approach With A2B530 to Bring CAR T Treatment to Solid Tumors

Kyle Doherty
June 17th 2023

The BASECAMP-1 clinical trial will aim to find patients with advanced solid tumors who are good candidates for the subsequent EVEREST trial.

Mustang Bio’s CAR-T MB-106 Achieves Responses in Waldenstrom Macroglobulinemia, Follicular Lymphoma

Mustang Bio’s CAR-T MB-106 Achieves Responses in Waldenstrom Macroglobulinemia, Follicular Lymphoma

Noah Stansfield
June 17th 2023

Two of 6 patients in the WM cohort achieved a complete response and 16 of 20 patients in the FL cohort achieved a complete response.

CGTLive’s Weekly Rewind – June 16, 2023

CGTLive’s Weekly Rewind – June 16, 2023

CGTLive Staff
June 16th 2023

Review top news and interview highlights from the week ending June 16, 2023.

Genetic Medicine in DMD: End Points, Assessment, and Approvals

Genetic Medicine in DMD: End Points, Assessment, and Approvals

Victoria Johnson
June 16th 2023

CGTLive takes a look at challenges that have beset the first gene therapy coming close to market for treating Duchenne muscular dystrophy in 2023.

Matthew Frank, MD, PhD, on Tackling Antigen Loss and Absence in Hematological Malignancies

Matthew Frank, MD, PhD, on Tackling Antigen Loss and Absence in Hematological Malignancies

Matthew Frank, MD, PhD
June 16th 2023

The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed potential methods for optimizing CAR-T efficacy that could be explored in the future.

Point-of-Care CAR T-Cell Therapy Yields 100% ORR in R/R CLL With or Without Richter’s Transformation

Point-of-Care CAR T-Cell Therapy Yields 100% ORR in R/R CLL With or Without Richter’s Transformation

Victoria Johnson
June 15th 2023

The phase 1/2 Euplagia-1 trial is currently ongoing in Europe.

Collaboration in Manufacturing is Key to Improving Patient Access for Gene Therapy and Cell Therapy

Collaboration in Manufacturing is Key to Improving Patient Access for Gene Therapy and Cell Therapy

Noah Stansfield
June 15th 2023

Betty Woo, the vice president and general manager of cell, gene, & advanced therapies at Thermo Fisher Scientific, discussed the challenges that exist in gene therapy and cell therapy manufacturing and potential solutions.

Susan Bal, MD, on Favorable Safety of BMS-986393 in R/R Multiple Myeloma

Susan Bal, MD, on Favorable Safety of BMS-986393 in R/R Multiple Myeloma

Susan Bal, MD
June 15th 2023

The assistant professor of medicine at University of Alabama – Birmingham discussed new data from the first-in-human trial of the CAR T-cell therapy.

Base-Edited CD7-CAR T Cells Show Early Efficacy in T-ALL

Base-Edited CD7-CAR T Cells Show Early Efficacy in T-ALL

Victoria Johnson
June 14th 2023

New data from 3 patients were published in the New England Journal of Medicine.

Around the Helix: Cell and Gene Therapy Company Updates – June 14, 2023

Around the Helix: Cell and Gene Therapy Company Updates – June 14, 2023

Noah Stansfield
June 14th 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Matthew Frank, MD, PhD, on Evaluating CD22-directed CAR-T CAR22 in R/R B-cell Malignancies

Matthew Frank, MD, PhD, on Evaluating CD22-directed CAR-T CAR22 in R/R B-cell Malignancies

Matthew Frank, MD, PhD
June 14th 2023

The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed the safety and efficacy results he presented at EHA’s 2023 congress.

Patient Death Prompts Pause in 2seventy bio's Trial for Acute Myeloid Leukemia CAR-T

Patient Death Prompts Pause in 2seventy bio's Trial for Acute Myeloid Leukemia CAR-T

Noah Stansfield
June 14th 2023

Seattle Children’s and 2seventy bio, which are collaborating on the development of SC-DARIC33, are currently investigating the cause of the grade 5 serious adverse event.

Binod Dhakal, MD, on Superior PFS With Cilta-Cel Compared to SOC in Multiple Myeloma

Binod Dhakal, MD, on Superior PFS With Cilta-Cel Compared to SOC in Multiple Myeloma

Binod Dhakal, MD
June 14th 2023

The associate professor at Medical College of Wisconsin discussed new findings from the CARTITUDE-4 study.

CAR-T WU-CART-007 Shows Evidence of Antileukemic Activity Among Patients With T-ALL/LBL

CAR-T WU-CART-007 Shows Evidence of Antileukemic Activity Among Patients With T-ALL/LBL

Noah Stansfield
June 13th 2023

The objective response rate among patients treated at DL2 and DL3 who were evaluable for efficacy was 57%.

Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-cel

Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-cel

Nausheen Ahmed, MD
June 13th 2023

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.

EDIT-301 Increases Total and Fetal Hemoglobin in Patents with Sickle Cell Disease

EDIT-301 Increases Total and Fetal Hemoglobin in Patents with Sickle Cell Disease

Victoria Johnson
June 13th 2023

The therapy seems to have a similar benefit in the first patient with TDT in the EdiTHAL trial.

Intellia’s CRISPR Gene Editing Therapy Significantly Reduces Swelling in Hereditary Angioedema, New Data Show

Intellia’s CRISPR Gene Editing Therapy Significantly Reduces Swelling in Hereditary Angioedema, New Data Show

Noah Stansfield
June 12th 2023

Intellia noted that the first 3 patients who received treatment reached at least 1 year of follow-up without experiencing HAE attacks.

Investigating CRB1 Mutations in Retinitis Pigmentosa 12

Investigating CRB1 Mutations in Retinitis Pigmentosa 12

Victoria Johnson
June 12th 2023

Sang Yoon Moon, PhD, postdoctoral Research Associate, Lions Eye Institute, discussed research with CRISPRa in human fibroblast cultures.

CAR-T CT103A Demonstrates Deep Responses in R/R Multiple Myeloma

CAR-T CT103A Demonstrates Deep Responses in R/R Multiple Myeloma

Noah Stansfield
June 11th 2023

Among 101 patients included in the efficacy analysis, the ORR was 96% and the CR rate was 74.3%.

Mary “Nora” Disis, MD, on Evaluating CAR-T PRGN-3005 in Ovarian Cancer

Mary “Nora” Disis, MD, on Evaluating CAR-T PRGN-3005 in Ovarian Cancer

Mary “Nora” Disis, MD
June 11th 2023

The director of University of Washington Medicine’s Cancer Vaccine institute discussed results from a phase 1 study presented at ASCO’s 2023 conference.

Lentiviral Gene Therapy Stabilizes Patients With MPS1H

Lentiviral Gene Therapy Stabilizes Patients With MPS1H

Victoria Johnson
June 10th 2023

Follow-up data up to 3 years showed supraphysiologic levels of blood IDUA and decrease of GAGs.

Wenjun (Tia) Li, on Reducing Swelling in Mouse Models of Rheumatoid Arthritis With Gene Therapy

Wenjun "Tia" Li, on Reducing Swelling in Mouse Models of Rheumatoid Arthritis With Gene Therapy

Wenjun (Tia) Li
June 10th 2023

The PhD candidate from University of North Carolina – Chapel Hill discussed preclinical research presented at ASGCT 2023.

FDA Accepts Exa-cel BLA for Sickle Cell and Transfusion-Dependent β-Thalassemia

FDA Accepts Exa-cel BLA for Sickle Cell and Transfusion-Dependent β-Thalassemia

Victoria Johnson
June 9th 2023

CRISPR Therapeutics and Vertex Pharmaceuticals completed their rolling submissions in April 2023.

<1
...
414243444546474849
...
173>
© 2024 MJH Life Sciences

All rights reserved.